Pure Bioscience

Pure Bioscience

Tom Y. Lee took Pure Bioscience public via reverse merger in 1996, anchoring the company on a proprietary silver-ion chemistry it calls silver dihydrogen citrate. Unlike traditional sanitizers that degrade quickly or leave toxic residues, SDC maintains residual antimicrobial activity on surfaces for extended periods. The intellectual property strategy is narrow: one core patent estate around SDC, licensed or sold as a concentrate to downstream formulators and distributors. The company operates across two vectors. Food safety — where SDC is approved for direct food contact sanitization in processing plants — and branded disinfectants for institutional consumers. Product examples include PURE Hard Surface, a ready-to-use disinfectant; PURE Multi-Purpose, sold into foodservice; and SDC-based formulations supplied to partners like Phase One Brands. Pure Bio's revenue model is a blend of concentrate sales to manufacturing partners and finished-goods distribution through channels such as Sysco. It also maintains relationships with chemical distributors in Asia, notably through a long-running partnership with Itochu for Japanese market access. Scale is modest. The company reported fewer than 50 employees in recent filings and operates from its El Cajon headquarters. Its shareholder base includes retail investors and the founding Lee family. In March 2022, the company secured a private placement of $3.25 million to fund continued commercial trials and working capital. There is no known investment vehicle for outside limited partners, though the firm has historically raised through equity offerings when commercial partnerships required scaling. The structural differentiator is a concentrated licensing and royalty model built around one molecule. Rather than competing across dozens of chemistry lines like Ecolab or Diversey, Pure Bioscience prosecutes SDC across regulatory environments — EPA, FDA, and international equivalents. This narrow bet means the business trades on regulatory milestones and single-partner adoption cycles, not diversified product pipelines. Succession is straightforward but unresolved: Tom Y. Lee remains the controlling shareholder and CEO, with no publicly disclosed plan for leadership transition.